Alto Neuroscience (ANRO) Competitors $2.24 -0.01 (-0.22%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$2.29 +0.04 (+2.00%) As of 04/17/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. LFCR, YMAB, SLRN, IMMP, PROK, HUMA, ITOS, SLDB, CRVS, and CRGXShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Lifecore Biomedical (LFCR), Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Immutep (IMMP), ProKidney (PROK), Humacyte (HUMA), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Corvus Pharmaceuticals (CRVS), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Lifecore Biomedical Y-mAbs Therapeutics Acelyrin Immutep ProKidney Humacyte iTeos Therapeutics Solid Biosciences Corvus Pharmaceuticals CARGO Therapeutics Alto Neuroscience (NYSE:ANRO) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends. Which has better valuation & earnings, ANRO or LFCR? Lifecore Biomedical has higher revenue and earnings than Alto Neuroscience. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$36.31M-$2.54-0.88Lifecore Biomedical$130.86M1.81$12.01M-$1.45-4.42 Do analysts recommend ANRO or LFCR? Alto Neuroscience presently has a consensus price target of $15.40, indicating a potential upside of 585.97%. Lifecore Biomedical has a consensus price target of $8.00, indicating a potential upside of 24.80%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alto Neuroscience is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ANRO or LFCR more profitable? Alto Neuroscience has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -12.52%. Alto Neuroscience's return on equity of -49.28% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -49.28% -33.52% Lifecore Biomedical -12.52%-315.23%-12.74% Does the MarketBeat Community believe in ANRO or LFCR? Alto Neuroscience received 13 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 84.21% of users gave Alto Neuroscience an outperform vote while only 25.00% of users gave Lifecore Biomedical an outperform vote. CompanyUnderperformOutperformAlto NeuroscienceOutperform Votes1684.21% Underperform Votes315.79%Lifecore BiomedicalOutperform Votes325.00% Underperform Votes975.00% Which has more volatility & risk, ANRO or LFCR? Alto Neuroscience has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ANRO or LFCR? 83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer ANRO or LFCR? In the previous week, Alto Neuroscience and Alto Neuroscience both had 4 articles in the media. Alto Neuroscience's average media sentiment score of 1.08 beat Lifecore Biomedical's score of 0.08 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAlto Neuroscience beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$60.91M$6.44B$5.30B$18.42BDividend YieldN/A3.23%5.12%4.20%P/E Ratio-0.886.8821.7331.10Price / SalesN/A231.02379.1626.58Price / CashN/A65.6738.2217.54Price / BookN/A5.916.444.30Net Income-$36.31M$142.72M$3.21B$1.02B7 Day Performance6.25%4.33%2.82%1.42%1 Month Performance-21.50%-12.80%-8.67%-7.33%1 Year Performance-83.42%-9.71%11.32%2.26% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience1.8753 of 5 stars$2.25-0.2%$15.40+586.0%-83.3%$60.91MN/A-0.88N/APositive NewsGap DownLFCRLifecore Biomedical1.1345 of 5 stars$6.17+6.0%$8.00+29.7%-1.8%$228.44M$130.86M-11.02690News CoverageYMABY-mAbs Therapeutics3.5183 of 5 stars$4.93+2.1%$18.30+271.2%-69.0%$222.93M$87.69M-9.13150Short Interest ↓Positive NewsSLRNAcelyrin3.5447 of 5 stars$2.18-2.2%$9.60+340.4%-56.2%$219.98MN/A-0.89135Short Interest ↓Gap DownIMMPImmutep1.0559 of 5 stars$1.49+2.1%$8.50+470.5%-31.9%$216.88M$5.14M0.002,021Gap DownPROKProKidney2.449 of 5 stars$0.74+1.2%$5.00+575.7%-72.2%$216.60M$76,000.00-1.353Insider TradeNews CoveragePositive NewsGap UpHUMAHumacyte2.5496 of 5 stars$1.49-2.6%$13.71+820.4%-46.2%$215.82M$1.57M-1.11150Positive NewsGap UpITOSiTeos Therapeutics2.2071 of 5 stars$5.53-2.1%$25.75+365.6%-39.0%$211.21M$35M-1.7690Short Interest ↑Positive NewsSLDBSolid Biosciences3.3537 of 5 stars$2.71+0.4%$15.67+478.1%-74.5%$210.01M$8.09M-0.89100CRVSCorvus Pharmaceuticals2.4637 of 5 stars$3.03+1.7%$15.67+417.1%+138.2%$206.45MN/A-3.2630Positive NewsGap UpCRGXCARGO Therapeutics2.6168 of 5 stars$4.46+4.7%$15.00+236.3%-76.2%$205.39MN/A-1.05116Positive News Related Companies and Tools Related Companies Lifecore Biomedical Competitors Y-mAbs Therapeutics Competitors Acelyrin Competitors Immutep Competitors ProKidney Competitors Humacyte Competitors iTeos Therapeutics Competitors Solid Biosciences Competitors Corvus Pharmaceuticals Competitors CARGO Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
